Dan Legault, CEO of Antibe Therapeutics Inc., on the company’s best-in-class pain/inflammation and regenerative medicine divisions.
Antibe is rather unique in the Canadian marketplace for having two best-in-class divisions. We have a biotech division and we have a commercial business with ten million dollars of revenue and this business is in regenerative medicine. Our drug development division is developing a family of potentially game-changing pain and inflammation therapeutics. Our lead drug is a derivative of Naproxen, one of the most prescribed medicines in the world. Naproxen, like all the drugs in its class, can cause very bad ulcers and bleeding in about 20% of people. Our lead drug in contrast, is safe. It would be game-changing for close to a billion people around the world. We recently announced that we have begun the formal IND enabling portion of development on our second drug, which is a super strong painkiller. Doctors would dearly love to be able to prescribe a safe but powerful and non-addictive painkiller. That is our second drug and we have a commercial division in regenerative medicine which is just a booming field. We sell a range of bone grafts and barrier membranes to Dental Surgeons and Oral Surgeons. We’re the market leader in Canada. We are starting to grow rapidly in the United States now and are poised to enter into Europe and Asia.
Antibe is a diversified biotechnology company with two best-in-class divisions in pain/inflammation and regenerative medicine. Its blockbuster drug platform has a lead asset in Phase 2, and the combined pipeline is targeting a global market opportunity in excess of $20 billion. Antibe’s commercial division in regenerative medicine is on a global growth trajectory in the dental biologics market.
Pursuing Blockbuster Drug Opportunities in Pain & Inflammation:
Antibe Therapeutics is pursuing a major advance in the safe and non-addictive treatment of pain and inflammation. Our drugs are designed to prevent the widespread and serious gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs (“NSAIDs”), today’s most widely used medicines for the relief of pain. The NSAID class of drugs includes prescription and over-the-counter (“OTC”) brands such as naproxen (Aleve), celecoxib (Celebrex), ibuprofen (Advil), and Aspirin.
Building a Commercial Force in Regenerative Medicine:
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products for oral and maxillofacial surgery. Since its inception in 1997, Citagenix has become an important source of knowledge and experience in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. More recently, Citagenix initiated a strategic growth initiative in the United States, the largest global market for oral regenerative medicine.
Antibe’s subsidiary, Citagenix, is leveraging its market leading position in Canada to pursue a global growth strategy in the dental biologics market.
For more information on Antibe Therapeutics Inc. (ATE.V) please fill out the form below.